Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | ILK | Q13418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140632 | 0.84 | CHRNA7 (0.36) | LCKITKAURKB | |
| SCHEMBL178961 | 0.75 | LCK (0.59) | LCKITKAURKB | |
| SCHEMBL4106848 | 0.69 | CLK2 (0.51) | CLK1CLK2HIPK1HIPK2CLK4 | |
| SCHEMBL143028 | 0.67 | ITK (0.70) | LCKITKAURKB | |
| SCHEMBL143029 | 0.67 | ITK (0.70) | LCKITKAURKB | |
| SCHEMBL6125608 | 0.63 | GRM4 (0.41) | ROCK2ROCK1 | |
| SCHEMBL29470394 | 0.63 | GRM4 (0.41) | ROCK2ROCK1 | |
| SCHEMBL2395088 | 0.63 | ITK (0.43) | CLK2LCKITKAURKB | |
| SCHEMBL2395099 | 0.63 | ITK (0.43) | CLK2LCKITKAURKB | |
| SCHEMBL2743540 | 0.63 | ILK (0.43) | CLK1CLK2HIPK1HIPK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | CLK1 338/4885CLK2 227/4885HIPK1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.